{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:11:59Z","timestamp":1784139119154,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.eururo.2015.02.022","type":"journal-article","created":{"date-parts":[[2015,3,5]],"date-time":"2015-03-05T01:17:14Z","timestamp":1425518234000},"page":"611-617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Long-term Outcome of Patients with Frequently Recurrent Non\u2013muscle-invasive Bladder Carcinoma Treated with One Perioperative Plus Four Weekly Instillations of Mitomycin C Followed by Monthly Bacillus Calmette-Gu\u00e9rin (BCG) or Alternating BCG and Interferon-\u03b12b Instillations: Prospective Randomised FinnBladder-4 Study"],"prefix":"10.1016","volume":"68","author":[{"given":"Riikka","family":"J\u00e4rvinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Marttila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eero","family":"Kaasinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkki","family":"Rintala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirpa","family":"Aaltomaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka","family":"Kallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapani","family":"Liukkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veli-Matti","family":"Puolakka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjo","family":"Sepp\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Tuhkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"Vaarala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jouko","family":"Viitanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Bostr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2015.02.022_bib0130","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0135","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","article-title":"Should all patients with non\u2013muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study","volume":"55","author":"Gudjonsson","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0140","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.juro.2008.03.038","article-title":"Can early single dose instillation of epirubicin improve bacillus Calmette-Gu\u00e9rin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study","volume":"180","author":"Cai","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0145","first-page":"CD006885","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus epirubicin for Ta and T1 bladder cancer","author":"Shang","year":"2011","journal-title":"Cochrane Database Sys Rev"},{"key":"10.1016\/j.eururo.2015.02.022_bib0150","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-5347(05)67446-0","article-title":"Weekly mitomycin C followed by monthly bacillus Calmette-Gu\u00e9rin or alternating monthly interferon-\u03b12B and bacillus Calmette-Gu\u00e9rin for prophylaxis of recurrent papillary superficial bladder carcinoma","volume":"164","author":"Kaasinen","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0302-2838(02)00260-9","article-title":"Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma","volume":"42","author":"Kaasinen","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0160","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer. A comprehensive review of the published literature","volume":"21","author":"Botteman","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.eururo.2015.02.022_bib0165","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"JASA"},{"key":"10.1016\/j.eururo.2015.02.022_bib0170","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF00299720","article-title":"Cytostatic effect of different strains of Bacillus Calmette-Guerin on human blader cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha","volume":"20","author":"Rajala","year":"1992","journal-title":"Urol Res"},{"key":"10.1016\/j.eururo.2015.02.022_bib0175","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2010.11.038","volume":"59","author":"Oosterlinck","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0180","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0302-2838(03)00140-4","article-title":"Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study","volume":"43","author":"Kaasinen","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0185","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0022-5347(01)62377-2","article-title":"Results of randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Gu\u00e9rin versus mitomycin C alone in patients with superficial bladder cancer","volume":"160","author":"Witjes","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0255","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","volume":"67","author":"Solsona","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0195","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0200","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon \u03b1-2b for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0205","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon \u03b1-2b plus low dose bacillus Calmette-Gu\u00e9rin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Gu\u00e9rin alone previously failed","volume":"166","author":"O\u2019Donnell","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0210","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/1096-9098(200007)74:3<181::AID-JSO3>3.0.CO;2-F","article-title":"Prospective phase II trial of alternating intravesical bacillus Calmette- Gu\u00e9rin (BCG) and interferon alpha IIB in the treatment and prevention of superficial transitional cell carcinoma of the urinary bladder: preliminary results","volume":"74","author":"Bazarbashi","year":"2000","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0215","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","volume":"184","author":"Nepple","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0220","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1464-410X.2010.10040.x","article-title":"Co-administration of intravesical bacillus Calmette-Gu\u00e9rin and interferon \u03b1-2b as first line in treating superficial transitional cell carcinoma of the urinary bladder","volume":"108","author":"Bazarbashi","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2015.02.022_bib0225","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","article-title":"Long-term efficacy of maintenance bacillus Calmette-Gu\u00e9rin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without CIS: a subgroup analysis of the prospective, randomized FinnBladder I study with a 20-year follow-up","volume":"56","author":"J\u00e4rvinen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0230","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/00365599.2012.694906","volume":"46","author":"J\u00e4rvinen","year":"2012","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0235","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Gu\u00e9rin in patients with superficial bladder carcinoma","volume":"161","author":"Malmstr\u00f6m","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0240","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","article-title":"Randomized intergroup comparison of bacillus Calmette-Gu\u00e9rin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder","volume":"1","author":"Lamm","year":"1995","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0245","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin-C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.02.022_bib0250","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0022-5347(05)64556-9","article-title":"Perioperative single dose instillation of epirubicin or interferon-\u03b1 after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study--FinnBladder III long-term results","volume":"168","author":"Rajala","year":"2002","journal-title":"J Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815001840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815001840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T13:23:15Z","timestamp":1537795395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283815001840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0302283815001840"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2015.02.022","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Outcome of Patients with Frequently Recurrent Non\u2013muscle-invasive Bladder Carcinoma Treated with One Perioperative Plus Four Weekly Instillations of Mitomycin C Followed by Monthly Bacillus Calmette-Gu\u00e9rin (BCG) or Alternating BCG and Interferon-\u03b12b Instillations: Prospective Randomised FinnBladder-4 Study","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2015.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}